| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27369SS | |||
| Azide and BSA Free | NBP2-80862 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77288-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56588SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56513SS | |||
| Azide and BSA Free | NBP2-33214 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-23484SS | |||
| Azide and BSA Free | NBP2-81015 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56682SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | BC100-520SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76963-0.025mg | |||
![Western Blot: MyD88 Antibody (4D6) [NBP2-27369] - Normal human bronchial epithelial total cell lysate. Image from verified customer review.](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-Western-Blot-NBP2-27369-img0005.jpg "Western Blot: MyD88 Antibody (4D6) [NBP2-27369] - Normal human bronchial epithelial total cell lysate. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: MyD88 Antibody (4D6) [NBP2-27369] - Analysis of MyD88 antibody in MCF-7 cells using an isotype control (top) and MyD88 Antibody (bottom) at 5 ug/ml.](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-Immunocytochemistry-Immunofluorescence-NBP2-27369-img0002.jpg)
![Flow Cytometry: MyD88 Antibody (4D6) - BSA Free [NBP2-27369] - An intracellular stain was performed on Jurkat cells with MyD88 Antibody (4D6) NBP2-27369PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-BSA-Free-Flow-Cytometry-NBP2-27369-img0012.jpg)
![Western Blot: MyD88 Antibody (4D6) [NBP2-27369] - Analysis of MyD88 in A) human ovary, B) human prostate and Jurkat cell lysate in the C) absence and D) presence of immunizing peptide using this antibody. Goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-Western-Blot-NBP2-27369-img0001.jpg)
![Flow Cytometry: MyD88 Antibody (4D6) [NBP2-27369] - Intracellular analysis of MyD88 antibody in Jurkat cells using 0.5 ug. Shaded histogram represents cells without antibody; green represents isotype control; red represents MyD88 antibody. This antibody was used for this test, and an anti-mouse IgG PE conjugated secondary antibody.](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-Flow-Cytometry-NBP2-27369-img0003.jpg)
![Flow (Intracellular): MyD88 Antibody (4D6) [NBP2-27369] - Analysis using the Alexa Fluor (R) 488 conjugate of NBP2-27369. Staining of MyD88 antibody in Jurkat cells using 10 ul (0.5 ug) of MyD88 antibody. Green represents isotype control (20108); red represents anti-MyD88 antibody.](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-Flow-Intracellular-NBP2-27369-img0006.jpg)
![Flow Cytometry: MyD88 Antibody (4D6) [NBP2-27369] - An intracellular stain was performed on MCF7 cells with MyD88 (4D6) antibody NBP2-27369PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-Flow-Cytometry-NBP2-27369-img0007.jpg)
![Flow Cytometry: MyD88 Antibody (4D6) [NBP2-27369] - An intracellular stain was performed on MCF7 cells with MyD88 [4D6] Antibody NBP2-27369AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-Flow-Cytometry-NBP2-27369-img0008.jpg)
![Flow Cytometry: MyD88 Antibody (4D6) - BSA Free [NBP2-27369] - An intracellular stain was performed on Jurkat cells with MyD88 Antibody (4D6) NBP2-27369 (blue) and a matched isotype control MAB002 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-BSA-Free-Flow-Cytometry-NBP2-27369-img0009.jpg)
![Flow Cytometry: MyD88 Antibody (4D6) - BSA Free [NBP2-27369] - An intracellular stain was performed on U-937 cells with MyD88 Antibody (4D6) NBP2-27369 (blue) and a matched isotype control MAB002 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-BSA-Free-Flow-Cytometry-NBP2-27369-img0010.jpg)
![Flow Cytometry: MyD88 Antibody (4D6) - BSA Free [NBP2-27369] - An intracellular stain was performed on MCF7 cells with MyD88 Antibody (4D6) NBP2-27369F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.](http://images.novusbio.com/fullsize/MyD88-Antibody-4D6-BSA-Free-Flow-Cytometry-NBP2-27369-img0011.jpg)
![Western Blot: IFN-beta Antibody [NBP1-77288] - Independent Antibody Validation (IAV) via Protein Expression Profile in Human and Mouse Cell Lines. Loading: 15 ug of lysates per lane. Antibodies: IFN-beta NBP1-77288 (4 ug/mL), IFN-beta from Company B, (5 ug/mL) and beta-actin NBP1-76692 (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Western-Blot-NBP1-77288-img0008.jpg "<b>Independent Antibodies Validation. </b>Western Blot: IFN-beta Antibody [NBP1-77288] - Independent Antibody Validation (IAV) via Protein Expression Profile in Human and Mouse Cell Lines. Loading: 15 ug of lysates per lane. Antibodies: IFN-beta NBP1-77288 (4 ug/mL), IFN-beta from Company B, (5 ug/mL) and beta-actin NBP1-76692 (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: IFN-beta Antibody [NBP1-77288] - Analysis of paraffin-embedded human liver tissue using anti-IFN-beta at 5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Immunohistochemistry-Paraffin-NBP1-77288-img0004.jpg)
![<b>Expression of Tagged Proteins Validation. </b>Western Blot: IFN-beta Antibody [NBP1-77288] - Validation in Multiple Tissues and Recombinant ProteinLoading: 15 ug of lysates per lane.Antibodies: IFN-beta (4 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Western-Blot-NBP1-77288-img0005.jpg)
![Western Blot: IFN-beta Antibody [NBP1-77288] - Loading: 15 ug of lysates per lane.Antibodies: IFN-beta (4 ug/mL), IFN-beta , (5 ug/mL) and beta-actin (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Western-Blot-NBP1-77288-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: IFN-beta Antibody [NBP1-77288] - analysis of 4% paraformaldehyde-fixed mouse liver tissue labeling IFN-beta with 4243 at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-77288-img0001.jpg)
![Immunohistochemistry-Paraffin: IFN-beta Antibody [NBP1-77288] - Analysis of paraffin-embedded human liver tissue using anti-IFN-beta antibody at 2.5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/IFN-beta-Antibody-Immunohistochemistry-Paraffin-NBP1-77288-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: IFN-beta Antibody [NBP1-77288] - Analysis of IFN-beta Antibody on mouse N9 cell line. Dilution 1:200. Image from verified customer review.](http://images.novusbio.com/fullsize/antibody/nbp1-77288_rabbit-polyclonal-ifn-beta-antibody-immunocytochemistry-immunofluorescence-2042023134812.jpg)
![Immunocytochemistry/ Immunofluorescence: IFN-beta Antibody - BSA Free [NBP1-77288] - Validation of IFN-beta in Human Liver Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed human liver cells labeling IFN-beta with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).](http://images.novusbio.com/fullsize/nbp1-77288_rabbit-polyclonal-ifn-beta-antibody-2711202419463433.jpg)
![Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Hela cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the -39 kDa p38 MAPK protein phosphorylated at Thr180/Tyr182.](http://images.novusbio.com/fullsize/p38-[p-Thr180--p-Tyr182]-Antibody-Western-Blot-NB500-138-img0005.jpg "Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Hela cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the -39 kDa p38 MAPK protein phosphorylated at Thr180/Tyr182.")
![Immunohistochemistry-Paraffin: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Immunostaining of human breast cancer tissue showing p38 when phosphorylated at Thr180/Tyr182 in red.](http://images.novusbio.com/fullsize/p38-[p-Thr180-p-Tyr182]-Antibody-Immunohistochemistry-Paraffin-NB500-138-img0002.jpg)
![Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Western blot of HeLa cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the ~39k p38 MAPK protein phosphorylated at Thr180/Tyr182.](http://images.novusbio.com/fullsize/p38-[p-Thr180-p-Tyr182]-Antibody-Western-Blot-NB500-138-img0001.jpg)
![Western Blot: p38 alpha [p Thr180, p Tyr182] Antibody [NB500-138] - RIP2 is not essential for MAPK pathways in the early ontogenesis. (A) Immunoblot analysis of phospho-p44/42 MAPK, p44/42 MAPK, & p38 MAPK in larvae homogenate from WT & NOD1-1IS−/− zebrafish at 7 days post-fertilization (dpf). (B) Immunoblot analysis of phospho-p44/42 MAPK, p44/42 MAPK, & p38 MAPK in larvae homogenate from WT & RIP2−/− zebrafish at 7 dpf. (C) Immunoblot analysis of Atg5, p62, & LC3b in larvae homogenate from WT & NOD1-1IS−/− zebrafish at 7 dpf. (D) Immunoblot analysis of Atg5, p62, & LC3b in larvae homogenate from WT & RIP2−/− zebrafish at 7 dpf. Western blotting results were quantified using Quantity One software. Data represent the average of two independent experiments. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29692779), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-138_rabbit-polyclonal-p38-alpha-p-thr180-p-tyr182-antibody-31020241534371.jpg)
![Immunocytochemistry/ Immunofluorescence: CD81 Antibody (M38) [NBP1-44861] - CD81 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line but is not detected in CD81 knockout (KO) HeLa cell line using Mouse Anti-Human CD81 Monoclonal Antibody (Catalog # NBP1-44861) at 15 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the plasma membrane.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Knockout-Validated-NBP1-44861-img0006.jpg "<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: CD81 Antibody (M38) [NBP1-44861] - CD81 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line but is not detected in CD81 knockout (KO) HeLa cell line using Mouse Anti-Human CD81 Monoclonal Antibody (Catalog # NBP1-44861) at 15 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the plasma membrane.")
![<b>Genetic Strategies Validation. </b>Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Surface staining pattern of human peripheral blood stained using anti-human CD81 (M38) purified antibody (concentration in sample 4 ug/ml) GAM APC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0010.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Surface staining of CD81 in human peripheral blood with anti-CD81 (M38) APC-CyTM7.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0001.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Human peripheral blood with anti-CD81 (M38) APC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0002.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Human peripheral blood with anti-CD81 (M38) FITC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0003.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Flow Cytometry: CD81 Antibody (M38) [PE] [NBP1-44861PE] - A cell surface stain was performed on THP-1 cells with CD81 antibody (M38) NBP1-44861 (blue) and a matched isotype control NBP2-27287 (orange). Cells were incubated in an antibody dilution of 1:100 for 20 minutes at room temperature. Both antibodies were conjugated to PE. Image using the PE form of this antibody.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0004.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Staining of CD81 in human peripheral blood with anti-CD81 (M38) PE.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0005.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Staining of CD81 in human peripheral blood with anti-CD81 (M38) PE.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0007.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Staining of CD81 in human peripheral blood with anti-CD81 (M38) biotin, streptavidin-APC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0008.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Separation of human lymphocytes (red-filled) from neutrophil granulocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD81 (M38) purified antibody (concentration in sample 4 ug/ml) GAM APC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0009.jpg)
![Flow Cytometry: TLR7 Antibody [NB100-56588] - Intracellular flow analysis of TLR7 in 10^6 ThP1 cells using 2 ug of NB100-56588. Shaded histogram represents cells without antibody. Green: isotype control. Red: TLR7 antibody. Intracellular flow kit was used for this test, and an anti-rabbit IgG PE conjugated secondary.](http://images.novusbio.com/fullsize/TLR7-Antibody-Flow-Cytometry-NB100-56588-img0001.jpg "Flow Cytometry: TLR7 Antibody [NB100-56588] - Intracellular flow analysis of TLR7 in 10^6 ThP1 cells using 2 ug of NB100-56588. Shaded histogram represents cells without antibody. Green: isotype control. Red: TLR7 antibody. Intracellular flow kit was used for this test, and an anti-rabbit IgG PE conjugated secondary.")
![Flow Cytometry: TLR7 Antibody [NB100-56588] - Analysis using the PE conjugate of NB100-56588. Staining of TLR7 in human PBMCs (monocytes) using 0.5 ug/10^6 cells of NBP2-24761. The shaded histogram represents cells alone. Green: PE-conjugated rabbit IgG isotype control (20304D). Red: TLR7 antibody.](http://images.novusbio.com/fullsize/TLR7-Antibody-Flow-Cytometry-NB100-56588-img0006.jpg)
![Immunohistochemistry-Paraffin: TLR7 Antibody [NB100-56588] - Analysis of FFPE human brain using TLR7 antibody at 1:20 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10 mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Neuronal staining of TLR7 was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/TLR7-Antibody-Immunohistochemistry-Paraffin-NB100-56588-img0007.jpg)
![Flow (Intracellular): TLR7 Antibody [NB100-56588] - Analysis using the FITC conjugate of NB100-56588. Staining of TLR7 in TLR7/HEK 293 cells using this antibody at 2 ug/10^6 cells. Green: Vector/HEK 293 cells. Red: TLR7/HEK 293 cells.](http://images.novusbio.com/fullsize/TLR7-Antibody-Flow-Intracellular-NB100-56588-img0004.jpg)
![Western Blot: IKK beta Antibody (10A9B6) [NB100-56513] - IKK beta in Daudi cell lysate using IKK beta antibody at 5 ug/ml.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10A9B6-Western-Blot-NB100-56513-img0005.jpg "Western Blot: IKK beta Antibody (10A9B6) [NB100-56513] - IKK beta in Daudi cell lysate using IKK beta antibody at 5 ug/ml.")
![Immunohistochemistry-Frozen: IKK beta Antibody (10A9B6) [NB100-56513] - Mouse skin tissue section stained with IKK beta antibody. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10A9B6-Immunohistochemistry-Frozen-NB100-56513-img0013.jpg)
![Flow (Intracellular): IKK beta Antibody (10A9B6) [NB100-56513] - Analysis using the Alexa Fluor (R) 488 conjugate. Staining of IKK in HEK 293 cells using 0.1 ug of this antibody. Green histogram represents the isotype control , red represents the IKK antibody. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10A9B6-Flow-Intracellular-NB100-56513-img0011.jpg)
![Simple Western: IKK beta Antibody (10A9B6) [NB100-56513] - Analysis using Azide Free version of NB100-56513. Lane view shows a specific band for IKK beta in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. *Non-specific interaction with the](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10A9B6-Simple-Western-NB100-56513-img0010.jpg)
![Immunoprecipitation: IKK beta Antibody (10A9B6) [NB100-56513] - Antibody was used to immunoprecipitate IKKb from 1x10^6 Daudi cells and the immuno-precipitated protein was detected by western blotting using NB100-56509. IKKb was detected as a protein of ~87 kD. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10A9B6-Western-Blot-NB100-56513-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Methanol-fixed MEF cells](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser536]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-82088-img0009.jpg "Immunocytochemistry/Immunofluorescence: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Methanol-fixed MEF cells")
![Immunohistochemistry-Paraffin: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Paraffin-embedded human breast carcinoma tissue.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser536]-Antibody-Immunohistochemistry-Paraffin-NB100-82088-img0007.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Paraffin-embedded human Lung carcinoma tissue](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser536]-Antibody-Immunohistochemistry-Paraffin-NB100-82088-img0008.jpg)
![Western Blot: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Western Blot analysis of various cells using NB100-82088 diluted at 1:2000](http://images.novusbio.com/fullsize/nb100-82088_rabbit-polyclonal-rela-nfkb-p65-p-ser536-antibody-23420241545352.jpg)
![Immunocytochemistry/ Immunofluorescence: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Immunofluorescence staining of methanol-fixed Hela cells using NB100-82088.](http://images.novusbio.com/fullsize/nb100-82088_rabbit-polyclonal-rela-nfkb-p65-p-ser536-antibody-103202523464512.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 [p Ser536] Antibody [NB100-82088] - Analysis of paraffin-embedded human breast carcinoma tissue using NB100-82088 incubated with blocking peptide (right)](http://images.novusbio.com/fullsize/nb100-82088_rabbit-polyclonal-rela-nfkb-p65-p-ser536-antibody-103202523464555.jpg)
![Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0014.jpg "<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunocytochemistry-Immunofluorescence-NBP2-23484-img0009.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human cervical cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0006.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on U-87 cells with ZEB1 [2A8A6] Antibody NBP2-23484AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0012.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 expression was assayed in lung adenocarcinoma cells after transfectionwith miR-33b or miR-NC, anti-miR-33b or anti-miR-NC in H1299 and A549 cells. Image submitted by verified customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0013.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human recturm cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0004.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - Flow cytometric analysis of Hela cells using ZEB1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0007.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on with A549 cells with ZEB1 Antibody NBP2-23484PE and a a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0010.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on Jurkat with ZEB1 Antibody (2A8A6) NBP2-23484 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse F(ab)2 IgG (H+L) PE-conjugated Antibody (R&D Systems, F0102B)](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0011.jpg)
![Western Blot: RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - Inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer toTakada et al, 2004 for further details). PTD-p65-P6 suppresses TNF-induced NF-kB activation by 25% at 100 uM and completely at 150 uM, where as the control peptide, PTD or p65-P6 without PTD did not have any effect.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser529--p-Ser536]-Inhibitor-Peptide-Set-Western-Blot-NBP2-29321-img0015.jpg "Western Blot: RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - Inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer toTakada et al, 2004 for further details). PTD-p65-P6 suppresses TNF-induced NF-kB activation by 25% at 100 uM and completely at 150 uM, where as the control peptide, PTD or p65-P6 without PTD did not have any effect.")
![Western Blot: RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 (3) for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser529--p-Ser536]-Inhibitor-Peptide-Set-Western-Blot-NBP2-29321-img0013.jpg)
![Functional (Inhibition): RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-29321) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-p-Ser529-p-Ser536-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-29321-img0012.jpg)
![Immunohistochemistry: TLR7 Antibody [NB100-56682] - Sections of nasal biopsies were incubated with antibodies against TLR9 (C) visualized by 3, 3-diaminobenzidine (brown). In control slides (F), N-series universal negative control reagent was used. All sections were accompanied with a square magnification. All slides were counterstained with haematoxylin (blue). The figure shows one representative biopsy out of four (3 male, 1 female). The arrows indicate positive stained cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0098239) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR7-Antibody-Immunohistochemistry-NB100-56682-img0005.jpg "Immunohistochemistry: TLR7 Antibody [NB100-56682] - Sections of nasal biopsies were incubated with antibodies against TLR9 (C) visualized by 3, 3-diaminobenzidine (brown). In control slides (F), N-series universal negative control reagent was used. All sections were accompanied with a square magnification. All slides were counterstained with haematoxylin (blue). The figure shows one representative biopsy out of four (3 male, 1 female). The arrows indicate positive stained cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0098239) licensed under a CC-BY license.")
![Flow Cytometry: TLR7 Antibody [NB100-56682] - HNEC, Detroit-562 and FaDu were stained intracellularly with Ab against TLR7 (open histograms) or appropriate isotype control (shaded histograms) and analyzed by flow cytometry. Representative pictures from one out of three independent experiments are shown. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0098239) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR7-Antibody-Flow-Cytometry-NB100-56682-img0007.jpg)
![Immunohistochemistry: TLR7 Antibody [NB100-56682] - Epithelial cells from primary HNEC (B), Detroit-562 (H) and FaDu (N) were incubated with antibody against TLR7 and visualized by 3, 3-diaminobenzidine (brown). In controls, N-series universal negative control reagent was used (F, L, R). All cells were counterstained with haematoxylin (blue). The figure shows one representative staining out of three independent experiments. The markers in the figure are 50 um. The arrows indicate positive stained cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0098239) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR7-Antibody-Immunohistochemistry-NB100-56682-img0006.jpg)
![Western Blot: TLR7 Antibody [NB100-56682] - Analysis of TLR7 in Ramos cell lysate using NB100-56682 at 1:500.](http://images.novusbio.com/fullsize/TLR7-Antibody-Western-Blot-NB100-56682-img0003.jpg)
![Immunohistochemistry-Paraffin: TLR7 Antibody [NB100-56682] - Analysis of TLR7 in formalin-fixed, paraffin-embedded human lung tissue using an isotype control (top) and this antibody (bottom) at 1:100.](http://images.novusbio.com/fullsize/TLR7-Antibody-Immunohistochemistry-Paraffin-NB100-56682-img0004.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein. OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE and subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600-667 of isoform 1 of OS-9. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0019151), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-BC100-520-img0004.jpg "Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein. OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE and subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600-667 of isoform 1 of OS-9. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0019151), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: OS9 Antibody [BC100-520] - OS9 antibody was tested in HeLa cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/OS9-Antibody-Immunocytochemistry-Immunofluorescence-BC100-520-img0002.jpg)
![Western Blot: OS9 Antibody [BC100-520] - WB analysis of OS9 in 1. A431 cell lysate, 2. HepG2 cell lysate, 3. MCF7 cell lysate and 4. 3T3 cell lysate.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-BC100-520-img0001.jpg)
![Simple Western: OS9 Antibody [BC100-520] - Simple Western lane view shows a specific band for OS9 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/OS9-Antibody-Simple-Western-BC100-520-img0003.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482216.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415483621.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482293.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Cellular localization of OS-9 & PHD2.(A) A lectin gel-shift assay was conducted to test for glycosylated proteins. Total cell lysates of U2OS cells were incubated in the presence or absence of the endoglycosidases EndoH & PNGaseF for 6 h at 37°C. Digest products were separated on a reducing 10% SDS-PAGE gel which contained concanavalin A co-polymerized in the top layer of the separating gel to retard mobility of glycosylated proteins [56]. Glycosylated OS-9 is indicated as ‘g’, deglycosylated OS-9 as ‘d’. (B) Detection of OS-9 & PHD2 in the nuclear fraction. HEK293 cells with & without transfection of the plasmid pcDNA3-OS-9 were separated into nuclear fraction (N) & postnuclear supernatant (PS), the latter containing cytoplasm & organelles. Western blot analysis included BiP, GAPDH & lamin A as typical marker proteins for the ER, the cytoplasm & the nucleus, respectively. (C) Detection of OS-9 & PHD2 in the cytoplasm. HEK293 cells were co-transfected with pcDNA3-OS-9 & pPHD2-V5. For hypoxia, cells were exposed to 3% O2 for 4 h. Cells were treated with 50 µg/ml digitonin & centrifuged to obtain a cytoplasmic (C) & an organelle fraction (O) & subjected to immunoblotting. (D) Isolation of cellular endomembranes. HEK293 cells were lysed mechanically by several passages through a 30½G needle. The postnuclear supernatant was processed further by ultra-centrifugation to separate the organelles (O) from the cytosol (C). High salt treatment (1 M KCl) of the organelle fraction produced a wash fraction (W) that contained dissociated peripheral membrane proteins. For immunoblot analysis of subcellular fractionations, cell aliquots were normalized for cell number prior to loading (B–D). Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415483637.jpg)
![Western Blot: OS9 Antibody [BC100-520] - OS-9 shows no effect on regulation of HIF-1 alpha .Total cell lysates were used for SDS-PAGE & subsequent Western blotting. To generate nearly anoxic conditions, cells were exposed to an oxygen consuming chemical system or to 1% or 3% O2 for 4 h to generate hypoxia. (A) U2OS, HeLa & Hep3B cells were transiently transfected with the plasmid pOS-9-V5 48 h prior to the experiment. Lamin A & actin were used as loading controls. (B) U2OS cells were subjected to ER stress by incubation either with tunicamycin (1 µg/ml) or thapsigargin (0.5 µg/ml) for 20 h. To detect HIF-1 alpha under normoxia, cells were treated with DMOG (1 mM) for 4 h. A sample of DMSO-only treated cells was loaded to exclude unspecific side effects of the solvent. (C) U2OS cells were transduced with lentiviral construct pLKO.1-shRNA-OS-9 (shOS-9) mediating a stable knockdown of OS-9 expression. Control cells (c) were transduced with plasmid pLKO.1-puro. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482250.jpg)
![Western Blot: Bim Antibody [NBP1-76963] - Independent Antibody Validation (IAV) via Protein Expression Profile in Cell LinesLoading: 15 ug of lysates per lane.Antibodies: BIM NBP1-76963, (0.5 ug/mL), BIM NBP1-77118, (5 ug/mL), beta-actin (1 ug/mL) and GAPDH (0.02 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/Bim-Antibody-Western-Blot-NBP1-76963-img0012.jpg "<b>Independent Antibodies Validation. </b>Western Blot: Bim Antibody [NBP1-76963] - Independent Antibody Validation (IAV) via Protein Expression Profile in Cell LinesLoading: 15 ug of lysates per lane.Antibodies: BIM NBP1-76963, (0.5 ug/mL), BIM NBP1-77118, (5 ug/mL), beta-actin (1 ug/mL) and GAPDH (0.02 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation. </b>Western Blot: Bim Antibody [NBP1-76963] - Western Blot Validation in Rat Myeloma Cell line:Loading: 15 ug of rat myeloma YB2/0 cell lysate per lane.Antibodies: BIM NBP1-76963, (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate.](http://images.novusbio.com/fullsize/Bim-Antibody-Western-Blot-NBP1-76963-img0008.jpg)
![Western Blot: Bim Antibody [NBP1-76963] - Western Blot Validation in HeLa Cells. Loading: 15 ug of lysate per lane. Antibodies: Bim NBP1-76963, (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate. Bim antibody can detect all three human isoforms, including EL, L and S isoforms.](http://images.novusbio.com/fullsize/Bim-Antibody-Western-Blot-NBP1-76963-img0009.jpg)
![Western Blot: Bim Antibody [NBP1-76963] - Western Blot Validation in Human Cell LinesLoading: 15 ug of lysates per lane.Antibodies: BIM NBP1-76963, (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/Bim-Antibody-Western-Blot-NBP1-76963-img0010.jpg)
![Western Blot: Bim Antibody - BSA Free [NBP1-76963] - Figure 3 Western Blot Validation in Human TissueLoading: 15 u of lysates per lane.Antibodies: BIM , (0.5 u/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Lane 1: Human thymusLane 2: Human colon](http://images.novusbio.com/fullsize/nbp1-76963_rabbit-polyclonal-bim-antibody-2711202420115554.gif)
![Immunocytochemistry/ Immunofluorescence: Bim Antibody - BSA Free [NBP1-76963] - Validation of BIM in K562 Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed K562 cells labeling Bim with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).](http://images.novusbio.com/fullsize/nbp1-76963_rabbit-polyclonal-bim-antibody-271120242045646.gif)